Heron Therapeutics Inc vs Nerdwallet Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Nerdwallet Inc trades at $9.22 (market cap $603.70M). The key difference: Nerdwallet Inc is far larger — about 6.6× Heron Therapeutics Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | NRDS | |
|---|---|---|
Market Cap | $91.46M | $603.70M |
Sector | Health | Financials |
52-Week High | $1.96 | $15.93 |
52-Week Low | $0.39 | $7.58 |
Enterprise Value | $189.36M | $518.00M |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
NerdWallet (NRDS) trades at $9.17, down 0.97% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected. Revenue grew to $836.6M in 2025 with improving net margins from -1.9% in 2022 to 5.82%. Valuation metrics appear attractive with P/E of 9.96 and P/S of 0.81. Recent news highlights the company's pivot to higher-margin transactions and launch of financial resilience indices.
The stock presents a compelling value opportunity with 39% upside to the $12.75 consensus target. Strong profitability metrics (93% gross margin, 19.47% ROE) and positive cash flow trends support the bullish case. Key risks include search-driven revenue headwinds and competitive pressures in financial guidance markets. Analyst consensus leans bullish with 4 buy ratings versus 1 hold and 1 sell.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →